Revolution Medicines, Inc. - Common Stock (RVMD) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RVMD on Nasdaq
Shares outstanding
186,164,820
Price per share
$79.65
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
191,763,478
Total reported value
$8,954,921,999
% of total 13F portfolios
0.02%
Share change
+1,001,009
Value change
+$87,457,256
Number of holders
316
Price from insider filings
$79.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revolution Medicines, Inc. - Common Stock (RVMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 7.9% +16% $511,649,696 +$74,497,980 13,262,045 +17% Dapice Joshua J. 31 Dec 2024
JANUS HENDERSON GROUP PLC 6.1% +6.7% $530,327,722 +$35,740,771 11,356,054 +7.2% JANUS HENDERSON GROUP PLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 5.5% $394,999,913 10,259,738 Wellington Management Group LLP 30 Jun 2025
FMR LLC 5% $439,058,769 9,401,687 FMR LLC 30 Sep 2025
BAKER BROS. ADVISORS LP 5% $360,551,422 9,364,972 Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 4.5% $309,009,603 8,399,214 BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 316 institutional investors reported holding 191,763,478 shares of Revolution Medicines, Inc. - Common Stock (RVMD). This represents 103% of the company’s total 186,164,820 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Revolution Medicines, Inc. - Common Stock (RVMD) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.4% 15,663,094 -0.63% 0.01% $731,466,490
FARALLON CAPITAL MANAGEMENT LLC 7.9% 14,625,692 +2.1% 3.9% $683,019,816
JANUS HENDERSON GROUP PLC 6.1% 11,356,054 +7.2% 0.24% $530,307,153
WELLINGTON MANAGEMENT GROUP LLP 5.3% 9,813,436 -4.4% 0.08% $458,287,462
BAKER BROS. ADVISORS LP 5.1% 9,455,357 +0.97% 3.2% $441,565,172
FMR LLC 5.1% 9,401,687 +13% 0.02% $439,058,770
BlackRock, Inc. 4.5% 8,327,758 -3.9% 0.01% $388,906,300
Nextech Invest, Ltd. 4.1% 7,601,087 0% 54% $354,970,763
Paradigm Biocapital Advisors LP 3.3% 6,223,291 +2.1% 8.6% $290,627,690
Bellevue Group AG 3% 5,573,838 +22% 5.4% $260,298,235
STATE STREET CORP 2.8% 5,254,639 +11% 0.01% $245,391,641
T. Rowe Price Investment Management, Inc. 2.6% 4,782,318 +2% 0.14% $223,335,000
Alphabet Inc. 2.2% 4,133,277 0% 8% $193,024,036
BVF INC/IL 2.1% 3,974,913 -20% 7.5% $185,628,437
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 3,873,706 -18% 0.02% $180,903,000
DEERFIELD MANAGEMENT COMPANY, L.P. 2% 3,650,342 +7.9% 2.6% $170,470,971
Holocene Advisors, LP 1.8% 3,437,283 -5.4% 0.37% $160,521,116
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,145,640 +5.1% 0.01% $146,932,051
Woodline Partners LP 1.6% 2,915,883 +0.01% 0.64% $136,171,736
a16z Capital Management, L.L.C. 1.5% 2,748,523 0% 9.2% $128,356,024
Casdin Capital, LLC 1.4% 2,647,333 -8.3% 10% $123,630,451
WESTFIELD CAPITAL MANAGEMENT CO LP 1.4% 2,513,967 +52% 0.49% $117,402,259
JPMORGAN CHASE & CO 1.3% 2,498,327 -12% 0.01% $116,671,883
GENERAL ATLANTIC, L.P. 1.3% 2,474,428 3.5% $115,555,788
Lunate Capital Ltd 1.2% 2,196,200 0% 46% $102,562,540

Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 71,619 $6,628,679 +$539,908 $79.65 15
2025 Q3 191,763,478 $8,954,921,999 +$87,457,256 $46.70 316
2025 Q2 190,726,235 $7,017,009,498 -$4,134,347 $36.79 305
2025 Q1 191,051,347 $6,776,444,446 -$111,943,197 $35.36 281
2024 Q4 193,048,484 $8,445,124,761 +$672,301,180 $43.74 278
2024 Q3 170,577,261 $7,735,337,873 +$69,484,732 $45.35 252
2024 Q2 168,410,110 $6,536,274,916 +$309,463,084 $38.81 221
2024 Q1 160,549,965 $5,174,502,235 +$41,971,613 $32.23 207
2023 Q4 159,991,814 $4,588,662,174 +$1,173,667,984 $28.68 183
2023 Q3 112,410,338 $3,111,480,815 +$13,449,543 $27.68 165
2023 Q2 111,960,439 $2,994,417,481 +$107,072,959 $26.75 138
2023 Q1 108,245,336 $2,343,498,970 +$420,665,649 $21.66 149
2022 Q4 88,251,337 $2,102,174,977 +$32,658,345 $23.82 133
2022 Q3 88,392,782 $1,743,047,001 +$233,806,685 $19.72 133
2022 Q2 76,461,750 $1,490,187,152 +$40,971,035 $19.49 125
2022 Q1 73,955,592 $1,885,584,241 +$15,751,102 $25.51 122
2021 Q4 73,332,089 $1,845,795,329 -$50,104,402 $25.17 113
2021 Q3 68,952,735 $1,896,915,710 +$49,809,012 $27.51 109
2021 Q2 70,364,140 $2,233,248,707 +$91,598,352 $31.74 127
2021 Q1 66,456,882 $3,048,913,145 +$424,322,383 $45.88 124
2020 Q4 57,426,011 $2,273,517,142 +$133,648,027 $39.59 118
2020 Q3 56,953,834 $1,981,075,717 +$339,721,674 $34.80 90
2020 Q2 46,886,789 $1,478,128,925 +$22,763,370 $31.57 73
2020 Q1 46,881,176 $1,025,119,285 +$1,024,845,284 $21.91 72